CD19 and acute lymphoblastic leukemia: We analysed eight patients (Supplementary Table 1) with relapsed or refractory B-ALL or LBCL following HSCT who were treated with piggyBac-modified CD19 CAR T cells (second generation) within a clinical trial28,29.